[HTML][HTML] Sleep disturbances associated with neurological autoimmunity

MF Devine, EK St Louis - Neurotherapeutics, 2021 - Elsevier
Associations between sleep disorders and neurological autoimmunity have been notably
expanding recently. Potential immune-mediated etiopathogenesis has been proposed for …

[HTML][HTML] Psychiatric sequelae of guillain-barre syndrome: towards a multidisciplinary team approach

C Hillyar, A Nibber - Cureus, 2020 - ncbi.nlm.nih.gov
Guillain-Barré syndrome (GBS) is a post-infectious autoimmune polyneuropathy. Recent
research has highlighted that GBS is associated with the onset of psychiatric symptoms …

[HTML][HTML] Rehabilitation outcomes in patients with post-COVID-19 vaccine-associated Guillain-Barre syndrome

A Gupta, A Ranga, NB Prakash… - Journal of Neurosciences …, 2022 - ncbi.nlm.nih.gov
Objective: With COVID-19 vaccination campaign worldwide, associated Guillain-Barre
syndrome (GBS) is being increasingly reported from different countries. The objectives of the …

[HTML][HTML] Respiratory involvement in Guillain–Barre syndrome: The uncharted road to recovery

M Garg - Journal of Neurosciences in Rural Practice, 2017 - thieme-connect.com
Guillain-Barre syndrome (GBS) is one of the most common causes of acute flaccid
quadriparesis with an incidence of 0.6-1.5/100,000. It is also one of the most common …

Fisioterapia respiratoria en pacientes con Síndrome Guillain Barré.

GE Cuji Moya, IJ Landa Pico - 2024 - dspace.unach.edu.ec
La fisioterapia respiratoria se basa en un conjunto de métodos, técnicas, procedimientos e
instrumentos utilizados en una diversidad de enfermedades, en especial las pulmonares o …

Assessment of Diaphragm Thickness by Ultrasonography in Guillain Barre Syndrome and Myasthenia Gravis

AA Naby, AE Zhran, S Ahmed, M Hazem… - …, 2022 - search.proquest.com
The diaphragmatic thickening ratio measured by ultrasonography in neurological diseases
remains unclear. Early prediction of diaphragmatic dysfunction may prevent the occurrence …

[引用][C] Minimizar la repercusión de los EA inmunomediados y maximizar la eficacia: toxicidades neurológicas

LP de AstraZeneca Pharmaceuticals